Arthroscopic meniscal procedures are the most commonly performed orthopaedic procedure in the U.S. affecting 15% of Americans ages 10-65 years. Meniscus injury is also known to increase the risk of posttraumatic osteoarthritis (PTOA). The current randomized clinical trial will test a novel intervention after meniscal repair that combines an oral senolytic fisetin and real-time biofeedback program to restore joint loading and subsequent return to activity.

开始日期2025-07-01

申办/合作机构

University of Kentucky

NCT06796374

/ Not yet recruitingN/AIIT

A Comparison of Fisetin Kinetics in Young and Old Adults - FISEKIN-1

This study investigates the differences in the kinetic parameters of fisetin in two cohorts of healthy volunteers:
Cohort 1) volunteers aged 18-30 years (n = 40) Cohort 2) volunteers aged 65 years or older (n = 40)
The purpose of this study is:
1. To describe the fisetin kinetics after a single dose oral administration in older age.
2. To compare the fisetin kinetics after a single dose oral administration in old and young age.
FISEKIN-1 is designed as a four-arm study protocol. As well as two different age groups (18-30 years vs. 65 years and older), we want to compare fisetin kinetic parameters in two different fisetin formulations and dosages :
Arm 1) 100 mg fisetin (1x 1 capsule), cohort 1: young age Arm 2) 100 mg fisetin (1x 1 capsule), cohort 2: old age Arm 3) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 1: young age Arm 4) 1000 mg fisetin + 200 mg quercetin (2x 1 softgel capsule), cohort 2: old age

开始日期2025-02-01

申办/合作机构

University of Greifswald

NCT06431932

/ Not yet recruiting临床1/2期IIT

Pharmacokinetics, Safety, and Efficacy of Fisetin - A Phase I and Pilot Phase IIa Study

The accumulation of senescent cells with age is a central mechanism that contributes to the development of chronic diseases, primarily by driving systemic chronic inflammation. Senolytic compounds such as fisetin can selectively target senescent cells for elimination and reduce multiple age-related pathologies in animal models.
We will conduct a clinical trial in healthy volunteers and older patients with multiple chronic diseases. The participants will receive fisetin or placebo for two days, after which they will be examined at regular intervals for up to three months. We will investigate how fisetin is absorbed and metabolized by the body, and whether fisetin is safe. We will also identify methods to best measure the effect of fisetin on chronic inflammation, senescent cells, and general health.

开始日期2025-01-01

申办/合作机构

Hvidovre University Hospital

[+2]

100 项与漆黄素相关的临床结果

登录后查看更多信息

100 项与漆黄素相关的转化医学

登录后查看更多信息

100 项与漆黄素相关的专利（医药）

登录后查看更多信息

3,527

项与漆黄素相关的文献（医药）

2025-05-01·Genes & Diseases

Targeting MUC1 with fisetin in oral squamous cell carcinoma

Article

作者: Xiang, Shuzhen ; Zhang, Lan ; Liu, Minda ; Wang, Qian ; Zhang, Hongyan ; Zhao, Fengfei ; Dai, Wei ; Xu, Zengyan ; Fan, Jiajia ; Li, Yanshu

2025-05-01·TALANTA

Metabolic signatures by LC-HRMS/MS of jabuticaba (Plinia cauliflora) juice, liqueur, and wines reveal the wealthiest sources of bioactive metabolites

Article

作者: Lima, Nerilson M ; Silva, Patricia A ; Vaz, Boniek G ; de Jesus A S Andrade, Teresinha ; Lima, Gesiane S ; Carli, Alessandra P ; Santos, Gabriel F ; Alves, Caio Cesar S ; Castro, Sandra B R ; Dias, Leandro S

This study aimed to determine the total phenolic content, antioxidant and anti-inflammatory activities, and metabolomic profiling of Jabuticaba beverages. The metabolomic profiling showed a greater abundance of flavonoids in liqueur samples, while sweet wine predominantly contained phenolic acids. On the other hand, dry wine was characterized by a higher abundance of terpenes. The total phenolic content (TPC) was determined by the Folin-Ciocalteu method, while antioxidant activity was evaluated using the DPPH radical-scavenging assay. Notably, dry wine was rich in anthocyanins and tannins and demonstrated the highest TPC (2985.08 ± 0.23 mg GAE/L). Furthermore, this sample exhibited superior antioxidant activity (IC₅₀ 0.83 ± 0.005 μg/mL). All beverages' samples displayed excellent antioxidant potential and TPC ranking as: dry wine > liqueur > sweet wine > juice. In terms of anti-inflammatory activity, treatments with 5 % dry wine led to reduce NO production. Molecular networking and chemometric tools, including HCA and PLS-DA, were employed to differentiate the samples and identify key metabolites. Chemometric analysis showed similar molecular composition between liqueur and dry wine samples, with the primary differences observed in their content of phenolic acids and simple phenols.

2025-04-01·EUROPEAN JOURNAL OF NUTRITION

Fisetin alleviates Salmonella typhimurium-induced colitis through the TLR2/TLR4-NF-κB pathway, regulating microbiota, and repressing intracellular bacterial proliferation by focal adhesion kinase

Article

作者: Zhang, Xinyu ; Yang, Yang ; Li, Jun ; Yang, Ying ; Wu, Zhenlong

BACKGROUND:

Salmonella typhimurium is a pathogen responsible for millions of cases of gastroenteritis in both humans and animals. This study aimed to evaluate the hypothesis that fisetin administration could mitigate colon damage and regulate the intestinal microbiota in mice treated with Salmonella typhimurium.

METHODS:

Six-week-old male mice were orally administered with or without 100 mg/kg fisetin and infected with Salmonella typhimurium.

RESULTS:

Fisetin administration ameliorated Salmonella typhimurium-induced colitis as shown by the decreased body weight loss, lowered disease activity index score, reduced colon shortening, inflammatory infiltration, and apoptosis. Meanwhile, Salmonella typhimurium exposure upregulated colonic Tnf-α, Il-6, Il-1β, Ifn-β, Ccl2, Ccl8 relative expression and MDA and H₂O₂ concentrations, whereas lowered Il-10, Nrf2, Nqo1, Coq10b, and Gss abundance, all of which were ameliorated by fisetin treatment. Moreover, fisetin recovered the occludin, zonula occludens-1, and zonula occludens-2 protein abundance in response to Salmonella typhimurium administration. Further investigation demonstrated that the protective role of fisetin was related to the inactivation of the TLR2/TLR4-NF-κB pathway, upregulation of Lactobacillus, and reduction of Salmonella abundance. Additionally, fisetin could limit the intracellular Salmonella typhimurium proliferation, which was likely to be attributed to the inhibition of focal adhesion kinase.

CONCLUSION:

Together, our study elucidated the therapeutic potential of fisetin in ameliorating key aspects of colitis, including intestinal inflammation, oxidative stress, and barrier dysfunction, and these beneficial effects were mediated through the inactivation of the TLR2/TLR4-NF-κB pathway, the regulation of microbiota, and restricting the intracellular proliferation of Salmonella typhimurium by inhibiting focal adhesion kinase.

项与漆黄素相关的新闻（医药）

2025-01-09

·Business Wire

Bonerge Announces the New 108 Person Clinical Trial: Exploring Skin and Organ Anti-Aging Innovations

NEW YORK--( BUSINESS WIRE )--Bonerge announced the initiation of its clinical trial, focusing on Fisetin, Urolithin A, and Ergothioneine. Involving 108 participants, this trial aims to evaluate their combined effects on skin health and organ rejuvenation when taking orally, providing more reliable options for the market. Senolytics Research: Advancing the Science of Anti-Aging In recent years, Senolytics research has advanced rapidly, with institutions like the Mayo Clinic and Wake Forest University at the forefront. Despite fruitful research, identifying optimal applications to translate Senolytics into market solutions remains crucial. In October 2024, the Mayo Clinic published groundbreaking findings in Nature Aging, identifying 67 plasma proteins, with IL-23R emerging as a promising anti-aging biomarker 1 . The study explored various promising Senolytics, including Fisetin, demonstrating a positive response in reducing senescence-related proteins and indicating potential for organ rejuvenation via senescent cell clearance 2 . The concept of organ rejuvenation offering deeper insights into its systemic effects and guiding anti-aging strategies. Senolytics show strong potential for organ rejuvenation applications and promise broader future prospects. Bonerge’s Clinical Trial: Exploring Skin as the Key to Rejuvenation The skin, the largest organ of the human body, is the most visible indicator of aging and a key target for anti-aging. Bonerge has launched a clinical trial focused on skin anti-aging, involving 108 participants. The trial evaluates skin anti-aging effects by assessing factors like skin heme, skin inflammation, transepidermal water loss, wrinkles, skin elasticity, skin firmness, melanin levels, and skin tone. Spanning 56 days, it aligns with two skin regeneration cycles, providing a detailed analysis of these key skin health indicators. Three ingredients tested in the trail: Fisetin: Among natural ingredients, fisetin has the strongest activity in clearing senescent cells. Its core mechanism promotes apoptosis of senescent cells and reduces SASP (Senescence-Associated Secretory Phenotype) secretion, alleviating chronic inflammation and combating inflammaging 3 , contributing to organ rejuvenation. Urolithin A: A rising star in nutritional supplements, Urolithin A has shown significant anti-photoaging effects. Photoaging, primarily caused by UVA (ultraviolet A) radiation, accelerates skin aging. Urolithin A helps protect skin by reducing the senescent phenotype of skin fibroblasts triggered by UVA, lowering intracellular ROS (reactive oxygen species), and activating antioxidant enzymes. These actions collectively support skin health and combat the harmful effects of photoaging 4 . Ergothioneine : Currently recognized as the only antioxidant that targets mitochondria, it reduces oxidative damage within mitochondria, supporting energy production and potentially preventing cellular aging 5 . Key Focus: Exploring Individual Ingredients and Combined Synergies In this clinical trial, while examining the skin anti-aging effects of individual ingredients, the combination of the three ingredients have also been tested to explore the synergistic effects on skin health and anti-aging. Path Ahead: Trial Progress and Future Expectations The clinical trial is progressing as planned and is expected to conclude in March 2025. Bonerge is hopeful that this study will provide valuable evidence for the anti-aging market, paving the way for the application of Senolytics in skin health and broader anti-aging treatments. References [1] Chase M. Carver, et al. IL-23R is a senescence-linked circulating and tissue biomarker of aging. Nature Aging, Dec 2024. [2] Researchers discover an aging and inflammation biomarker - Mayo Clinic News Network [3] Matthew J. et al. Fisetin is a senotherapeutic that extends health and lifespan. EBioMedicine 36 (2018). [4] Wenjie Liu , et al. Urolithin A protects human dermal fibroblasts from UVA-induced photoaging through NRF2 activation and mitophagy. J Photochem Photobiol B. 2022 Jul. [5] Brown, Lisa, et al. L-Ergothioneine and Its Protective Role in Cellular Health. Journal of Clinical Nutrition, vol 56.

临床研究

2024-12-31

·Business Wire

BeFisetin® is Gaining the First Fisetin Ingredient SA-GRAS Certification

NEW YORK--( BUSINESS WIRE )--In 2024, Bonerge's premium fisetin branded ingredient, BeFisetin®, initiated the SA-GRAS (Self-Affirmed Generally Recognized As Safe) certification process, with completion expected in February 2025. This certification underscores Bonerge's unwavering commitment to product safety, quality control and serves as a key milestone in its expansion into the global fisetin market. Fisetin: The Anti-aging Potential of Natural Polyphenols Fisetin is a natural polyphenol widely present in various fruits and vegetables such as strawberries, apples, and persimmons. In recent years, the scientific community's enthusiasm for exploring fisetin has been continuously rising. Numerous research findings have revealed that fisetin has unique biological properties in reducing inflammatory factors, strengthening cell health, and delaying aging [1-3], and its related applications have also attracted extensive and in-depth attention. Biochemical studies have shown that fisetin can exert its effects through multiple mechanisms. It can effectively reduce senescent cells in the brain, skin, and various organs, regulate inflammatory factors, and scavenge free radicals [4]. This makes fisetin an attractive dietary supplement, showing broad application prospects in healthy aging and long-term health management. BeFisetin®: Marketing Strategy and Innovation As a company dedicated to the development and research of high-quality ingredients, Bonerge recognizes the growing global demand for safe and effective dietary supplements. It is Bonerge’s principle to leverage cutting-edge science to transform advanced research into practical health solutions. Bonerge is continuously improving the purity and bioavailability of BeFisetin®, while integrating sustainable production practice, demonstrating a strong commitment to environmental responsibility. Focusing on the great potential of fisetin, Bonerge has engaged in in-depth strategic collaborations with multiple research institutions and universities to strengthen the scientific validation and credibility of BeFisetin®, continuously enhancing its trust and reputation through rigorous scientific verification. This ensures consumers have access to transparent, reliable health solutions. SA-GRAS Certification: An Extended Standard in Safety and Trust SA-GRAS certification, a critical extension of the FDA's GRAS framework, allows companies to confirm the safety of their products through rigorous self-assessment. This process involves establishing stringent product standards, conducting comprehensive toxicity and safety evaluations, and systematically assessing raw materials, manufacturing processes, and product stability. Companies need to work with independent professional organizations to prepare detailed safety assessment reports, which are reviewed by an expert panel. The rigorous certification process drives Bonerge to further optimize its product quality systems and elevated BeFisetin®'s competitiveness in the global market. For Bonerge, SA-GRAS certification is not merely a regulatory milestone but a testament to its relentless pursuit of product excellence and its commitment to consumer safety. Looking Ahead: Responsibility and Opportunity The expansion of aging population is a global challenge, driving increasing demand for health-focused anti-aging solutions. Bonerge is committed to leveraging BeFisetin®'s superior quality to advance scientific research, foster innovation, and provide consumers with safer and trustworthy products. To be or not to be, that is the question! BeFisetin®: A scientific breakthrough as the world’s first SA-GRAS-certified fisetin ingredient, setting a new industry standard. References [1] Yoon S, Lee H, Kim J, et al. A natural flavonoid, fisetin, alleviates neuroinflammation and memory impairment in D-galactose-treated mice[J]. Frontiers in Pharmacology, 2023, 14: 1134733. [2] Li X, Zhang H, Guo Y, et al. Fisetin promotes osteoblastogenesis and inhibits adipogenesis in bone marrow stromal cells through the activation of the Wnt/β-catenin pathway[J]. International Journal of Molecular Sciences, 2019, 20(23): 5957. [3] Yousefzadeh MJ, Zhu Y, McGowan SJ, et al. Fisetin is a senotherapeutic that extends health and lifespan[J]. EBioMedicine, 2018, 36: 18-28. [4] Takaya K, Kawaguchi M, Mizutani K, et al. Fisetin, a potential skin rejuvenation drug that eliminates senescent cells in the dermis[J]. Biogerontology, 2023, 24(5): 409-421.

2024-12-17

·生物世界

Nature Aging：梅奥医学中心发现新型衰老标志物——IL-23R

撰文丨王聪编辑丨王多鱼排版丨水成文细胞衰老是一种以细胞周期停滞和衰老相关分泌表型（SASP）为特征的衰老机制。临床前研究表明，靶向衰老细胞生存通路的抗衰老药物可对抗多个器官的年龄相关疾病。尚未有任何研究证实不同类型的衰老细胞清除药物在体内对改变衰老和衰老标志物的相对有效性。 2024年12月10日，梅奥医学中心的研究人员在 Nature Aging 期刊发表了题为：IL-23R is a senescence-linked circulating and tissue biomarker of aging 的研究论文。该研究表明，白细胞介素-23受体（IL-23R）是一种衰老相关的循环和组织生物标志物。细胞衰老是一种年龄相关机制，参与多种器官系统的发病，包括免疫功能障碍、心血管和代谢性疾病、肺纤维化、骨质疏松、肾脏疾病、肝损伤、肌肉减少症和认知功能下降等。衰老血液中的因子可驱动许多组织的衰老和炎症激活。但早衰循环因子的组织和细胞特异性起源尚未明确。来源于衰老细胞的循环蛋白可能反映全身衰老细胞负荷，可能被开发为诊断或预后生物标志物，并且可能是早衰器官间通讯的介质。在这项最新研究中，研究团队建立了衰老和衰老相关的血浆蛋白和组织转录物，它们在老年和年轻的小鼠中发生了变化。研究团队在老年p16-InkAttac小鼠中研究了Venetoclax（一种Bcl-2抑制剂）、Navitoclax（一种Bcl-2抑制剂）、fisetin（漆黄素）或luteolin（木犀草素）急性治疗与转基因衰老细胞清除之间的反应。结果显示，年龄依赖性的血浆蛋白变化，包括IL-23R、CCL5和CA13，被治疗药物逆转，这对应于组织的表达差异，特别是在肾脏。而在人的一生中，血浆中IL-23R随着年龄的增长而增加。这些结果揭示了循环因子作为与衰老相关的器官间信号转导的候选介质和全身衰老细胞负荷的生物标志物。论文链接： https://www-nature-com.libproxy1.nus.edu.sg/articles/s43587-024-00752-7 设置星标，不错过精彩推文开放转载欢迎转发到朋友圈和微信群微信加群为促进前沿研究的传播和交流，我们组建了多个专业交流群，长按下方二维码，即可添加小编微信进群，由于申请人数较多，添加微信时请备注：学校/专业/姓名，如果是PI/教授，还请注明。点在看，传递你的品味

100 项与漆黄素相关的药物交易

登录后查看更多信息

外链

KEGG	Wiki	ATC	Drug Bank
-	-	-	DB07795

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
系统性硬化相关的间质性肺病	临床2期	美国	Mayo Clinic	2023-04-12
腕管综合征	临床2期	美国	Mayo Clinic	2022-10-09
新冠肺炎后遗症	临床2期	美国	Mayo Clinic	2020-08-03
Crouzon综合征伴黑棘皮症	临床2期	美国	Mayo Clinic	2018-02-06
炎症	临床2期	美国	Mayo Clinic	2018-02-06
肾纤维化	临床前	中国	四川大学华西医院（四川省国际医院）	2023-03-01
黑色素瘤	临床前	美国	University of Wisconsin Madison	2013-04-15
前列腺癌	临床前	美国	University of Wisconsin Madison	2009-05-01
结肠癌	临床前	美国	University of Wisconsin Madison	2008-05-01

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT04210986 (CTgov)	临床1/2期	膝关节炎	75	Fisetin (Fisetin)	壓築淵壓膚糧窪選繭壓 = 選築餘壓簾糧構膚築鏇顧衊積鑰廠鏇構衊齋齋 (淵淵簾衊襯範選築鬱繭, 觸艱糧衊膚衊選遞夢窪 ~ 願膚糧壓遞簾廠蓋憲鹹) 更多	-	2024-09-19
				Placebo oral capsule (Placebo)	壓築淵壓膚糧窪選繭壓 = 鏇築窪淵築蓋膚繭築鹹顧衊積鑰廠鏇構衊齋齋 (淵淵簾衊襯範選築鬱繭, 網觸構獵鏇簾壓網蓋艱 ~ 窪衊廠壓艱簾蓋餘憲鑰) 更多
NCT04771611 (COVFIS-HOME, CTgov)	临床2期	新型冠状病毒感染	55	Fisetin (Treatment Group)	觸簾簾壓繭顧艱鏇醖廠 = 艱鹽淵淵獵衊範構鏇獵構襯構願網憲憲遞繭鏇 (齋壓鹹壓廠繭鬱糧淵範, 積簾顧積糧鏇築廠醖顧 ~ 醖選遞願觸顧鹹憲鏇壓) 更多	-	2023-08-01
				Placebo (Placebo)	觸簾簾壓繭顧艱鏇醖廠 = 簾網夢網淵膚糧獵壓醖構襯構願網憲憲遞繭鏇 (齋壓鹹壓廠繭鬱糧淵範, 廠製鹽繭齋窪觸構構製 ~ 蓋選憲選餘壓鹽餘鑰構) 更多